What Fleury does

Fleury S.A. is a Brazilian diagnostic medicine company founded in 1926 and listed on B3's Novo Mercado under ticker FLRY3. The company operates the country's most recognized diagnostic brand portfolio — including Fleury, Grupo Pardini, Weinmann, Femme, and a+ — and runs a nationwide network of Physical Service Centers (PSCs), a home-visit service (Fleury em Casa), and digital channels (website, mobile apps, Teleconsulta, B2C Marketplace) that together deliver laboratory tests, imaging, vaccinations, and specialty diagnostics across all life stages. Core technology consists of digital scheduling and results platforms, the epidemiological bulletins infoVirus and infoKids, and an integrated Health Platform/Marketplace that aggregates multiple service lines including diagnostics, drug infusion, orthopedics, and ophthalmology. The company also operates specialized centers for women's health, cardiology/neurovascular, dermatology, neurology, and thyroid diagnostics, and runs a fellowship program in diagnostic imaging.

Fleury generates revenue primarily on a transaction-fee basis through three core streams: B2C diagnostic services via PSCs and digital channels, B2B hospital and lab-to-lab partnership services, and vaccination offerings (with disclosed pricing such as R$ 210 for influenza, R$ 505 for dengue, R$ 1,098 for HPV, and R$ 914 for herpes-zoster). The Health Platform/Marketplace introduces subscription/recurring elements. Customers span individual consumers (the primary segment), hospital systems, diagnostic laboratories, and affiliated physicians — Fleury maintains a network of 4,900 affiliated physicians across a workforce of more than 22,400 as of end-2023. The company's go-to-market combines B2B field sales for hospitals and labs, direct-to-consumer digital scheduling, and channel partnerships for lab-to-lab referrals.

In FY2024, Fleury reported revenue of R$ 9 billion, EBITDA of R$ 2.1 billion, and net profit of R$ 96.3 million, with a market capitalization of R$ 8.7 billion. Strategic momentum is significant: 11 diagnostic acquisitions have been completed since 2017, with the most recent being Femme Laboratory for R$ 207.5 million (Nov 2025) and Laboratório São Lucas. In February 2026, parent Bradesco announced the consolidation of all healthcare assets — including Fleury — into a new listed entity called BradSaúde via reverse IPO through Odontoprev, creating a vertically integrated payor-provider-diagnostics platform with pro forma 2025 revenue of R$ 52 billion.

Name

Fleury

Legal name

Fleury S.A.

Website

https://www.fleury.com.br/

Company type

Public

Founded year

1926

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Fleury S.A. is Brazil's leading diagnostic medicine company, founded in 1926, operating Physical Service Centers, home-service, and digital channels to deliver laboratory tests, imaging, vaccinations, and specialty diagnostics to individual consumers, hospitals, and partner laboratories across Brazil.

Ownership category

akta.pro rank

Product category

Diagnostic Medicine Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Offices of Physicians (62111)

SIC

Services-Medical Laboratories (8071), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Pulmonary Function & Respiratory Diagnostic Centers (PFT/Spirometry) (HLAFAKAJ)

akta.pro secondary industry

Pulmonary Function Testing (PFT) & Respiratory Diagnostics (HLAKANAC)

Keywords

• Diagnostic medicine services
• Clinical laboratory testing
• Medical imaging diagnostics
• Vaccination services
• Preventive health check-ups

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Diagnostic Medicine Services (B2C): Core diagnostic medicine services delivered through Physical Service Centers (PSCs) directly to individual consumers across all life stages, including laboratory tests, imaging, and clinical analysis.
2. Diagnostic Medicine Services (B2B): Hospital and laboratory diagnostic services provided under B2B contracts, including enterprise agreements with healthcare systems and lab-to-lab referral arrangements.
3. Vaccination Services: Comprehensive vaccination services including influenza, dengue, HPV, and herpes-zoster vaccines offered at service centers and potentially through home service.
4. New Links Services: Extended healthcare services including drug infusion therapy, orthopedics, ophthalmology and other specialized medical services under the New Links initiative, creating new revenue streams beyond core diagnostics.
5. Health Platform Services: Digital marketplace services through the Health Platform enabling access to integrated healthcare services, potentially including telehealth and service coordination.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Fleury is a Brazilian diagnostic medicine company that delivers clinical laboratory tests, diagnostic imaging, vaccinations, and preventive health check-ups through a national network of Physical Service Centers, home visit services, and digital platforms. It serves individual consumers directly across all life stages (babies, children, adults, seniors, pregnant women) and provides enterprise diagnostic support to hospitals and clinical laboratories. Extended offerings include specialized centers in women's health, pediatrics, cardiology, neurology, and orthopedics, plus teleconsultation and a B2C digital health marketplace.

Product overview

Fleury is a comprehensive diagnostic medicine company operating a multi-channel healthcare platform. The offering consists of a core diagnostic medicine business (B2C, B2B, and hospital services), supplemented by specialized centers focused on women's health (Centro Diagnóstico Avançado da Mulher, Espaço Saúde da Mulher, Fleury Endometriose), pediatric care (Fleury Kids), cardiovascular and neurological health (Centro Integrado Cardiológico e Neurovascular, Fleury Neurologia), and other specialty areas. Digital services include home healthcare (Fleury em Casa), teleconsultation, and a B2C marketplace. The company also publishes epidemiological bulletins (infoVirus, infoKids) and offers vaccination services and fellowship education programs in diagnostic imaging.

Differentiator

Problem solved

Functional benefit

Brands

• Fleury em Casa: Home care diagnostic services
• Fleury Kids
• Check-up Fleury
• Espaço Saúde da Mulher

Products and services

• Diagnostic Medicine Services Core clinical laboratory testing, diagnostic imaging, and clinical analysis services delivered through Physical Service Centers (PSCs) and home service across Brazil. Includes routine bloodwork, pathology, molecular diagnostics, and imaging for individual consumers (all life stages) and B2B hospital/laboratory clients.
• Fleury em Casa Home healthcare service enabling patients to receive diagnostic sample collection, tests, and vaccinations in the comfort of their residence or chosen location.
• Vacinas (Vaccination Services) Comprehensive vaccination services including influenza (R$ 210), dengue (R$ 505), HPV (R$ 1,098), and herpes-zoster (R$ 914) vaccines delivered at service centers and via home service.
• Check-up Fleury Comprehensive health screening and check-up packages providing personalized general health assessment, with specialized variants such as Check-up Longevidade for preventive care in aging populations.
• Fleury Kids Specialized pediatric diagnostic and healthcare service tailored for children, marketed as the only laboratory with an in-house pediatrician present during pediatric service delivery.
• Women's Health Centers (Centro Diagnóstico Avançado da Mulher / Espaço Saúde da Mulher) Advanced diagnostic centers specializing in women's health, including mammography, gynecological imaging, and integrated consultation services for female patients. Located at Unidade Líbano II and other sites.
• Specialty Diagnostic Centers (Cardiology, Neurology, Dermatology, Allergy, Endocrinology, Orthopedics) Network of integrated specialty diagnostic centers covering cardiology, neurovascular, neurology, dermatology, allergy/immunology, thyroid nodules, and musculoskeletal imaging. Each center offers condition-specific testing and specialist consultations.
• Teleconsulta Teleconsultation service enabling remote medical consultations with Fleury physicians as part of the company's digital health platform.
• Marketplace B2C (Health Platform / Marketplace) Business-to-consumer digital marketplace for health services and products, aggregating diagnostics, vaccinations, drug infusion therapy, orthopedics, ophthalmology, and other specialized services under the New Links extended healthcare initiative.
• infoVirus and infoKids Epidemiological Bulletins Proprietary epidemiological intelligence publications: infoVirus tracks respiratory virus behavior in the general population; infoKids focuses on children's health and pediatric respiratory virus tracking. These bulletins reinforce Fleury's brand authority in disease surveillance.

Quantifiable outcome

• 13.4% service unit growth demonstrating operational scale and market expansion
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Bradesco (BradSaúde)coreStrategic or Co-development PartnerBradesco consolidation into BradSaúde via reverse IPO represents a significant business consolidation involving Fleury's health insurance and diagnostic operations. This consolidation creates one of Brazil's largest health insurance platforms, combining diagnostic services with insurance coverage.
• Grupo PardinicoreStrategic or Co-development PartnerBusiness combination with Grupo Pardini announced in June 2022, combining two significant Brazilian diagnostic medicine players to create a more comprehensive service offering and expanded geographic reach.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Sonic Healthcare: Global pathology and radiology services provider operating laboratory networks in Australia, Europe and North America. Comparable to Fleury in operating multi-site diagnostic laboratories with strong physician-driven brand identity.
• Quest Diagnostics: One of the largest clinical laboratory networks in the US, offering routine and esoteric testing, anatomic pathology and employer health services. Comparable to Fleury as a scaled, multi-channel diagnostic services platform with B2B and B2C exposure.
• Laboratory Corporation of America (Labcorp): Global clinical laboratory and diagnostics leader with a broad routine and specialty testing menu serving physicians, hospitals, employers and patients. Comparable to Fleury in operating model, scale and breadth of diagnostic offerings.
• Eurofins Scientific: Global leader in bioanalytical testing and clinical diagnostics services across pharma, food, environment and clinical end-markets. Comparable to Fleury in laboratory services scope, though Eurofins is more diversified across non-clinical testing.
• Synlab: Europe's largest medical diagnostics services provider, operating clinical labs and specialty testing across multiple countries. Comparable to Fleury in PSC-style patient service centers and B2B laboratory services model.

Regional players

• Hospital Israelita Albert Einstein: Leading Brazilian hospital system that also operates diagnostic medicine services and outpatient labs. Comparable to Fleury as a premium Brazilian diagnostic provider, though its core business is hospital-based.

Direct peers

• Sabin Diagnóstico e Saúde: Major Brazilian diagnostic chain with extensive PSC presence in Central-Western and Southeastern Brazil. Comparable to Fleury in offering laboratory tests, imaging and vaccinations to B2C and B2B customers.
• Dasa (Diagnósticos da América): Brazil's largest diagnostic medicine company, operating a national network of labs, imaging centers and hospital diagnostics. Direct head-to-head competitor to Fleury across B2C, B2B hospital and lab-to-lab channels in Brazil.

Others

• Hapvida NotreDame Intermédica: Large Brazilian vertically integrated health plan and hospital network with embedded diagnostic capabilities. Comparable to Fleury as a healthcare ecosystem player in Brazil, though diagnostics is a supporting rather than primary line.
• Rede D'Or São Luiz: Brazil's largest hospital network with growing diagnostic and outpatient service lines. Comparable to Fleury as a Brazilian healthcare ecosystem participant; competes for some B2B diagnostic outsourcing and physician referrals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/fleurymedicinaesaude
• Facebookfacebook.com/FleuryMedicinaeSaude
• LinkedInlinkedin.com/company/fleury-s-a-
• Instagraminstagram.com/fleuryoficial
• Xx.com/fleury_online

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fleury